Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
Hemophilia A is characterized by a deficiency of clotting factor VIII (FVIII) requiring lifelong prophylactic treatment, typically with recombinant FVIII. In recent years, drugs with extended half-lives have become available, including damoctocog alfa pegol (Bayer S.p.A.). The clinical efficacy and...
Salvato in:
Autore principale: | |
---|---|
Natura: | Libro |
Pubblicazione: |
MDPI AG,
2023-08-01T00:00:00Z.
|
Soggetti: | |
Accesso online: | Connect to this object online. |
Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Accesso online
Connect to this object online.3rd Floor Main Library
Collocazione: |
A1234.567 |
---|---|
Copia 1 | Disponibile |